Stockreport

Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression

Kineta, Inc.  (KA) 
PDF SEATTLE, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in on [Read more]